Aripiprazole versus risperidone for treating children and adolescents with Tic disorder: A randomized double blind clinical trial
Child Psychiatry & Human Development, 12/20/2013 Ghanizadeh A, et al.
There are some uncontrolled studies about the efficacy and safety of both aripiprazole and risperidone for treating tic disorder. Moreover, the efficacy of these medications has never been compared. Their adverse effects and their effects on health related quality of life were comparable. However, risperidone increased the patients’ social functioning more than aripiprazole in short term.
This is the first double blind randomized clinical trial comparing the safety and efficacy of aripiprazole and risperidone for treating patients with tic disorder.
Sixty children and adolescents with tic disorder were randomly allocated into one of the two groups to receive either aripiprazole or risperidone for 2 months.
The primary outcome measure was the score of Yale Global Tic Severity Scale.
In addition, health related quality of life and adverse events were assessed.
Both aripiprazole and risperidone decreased the Yale Global Tic Severity Scale score during this trial. Moreover, both medications increased the health related quality of life score.
Both aripiprazole and risperidone were tolerated well.
Aripiprazole [3.22 (1.9) mg/day] decreased tic score as much as risperidone [0.6 (0.2) mg/day].
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.